Background {#Sec1}
==========

Hepatitis B virus (HBV) is an enveloped virus containing about 3.2 kb, partially double-stranded DNA genome and can be classified into eight genotypes (A to H) \[[@CR1]\]. Different genotypes have distinct geographic distributions, genotype A is pandemic, B and C are mainly prevalent in Asia, D in southern Europe, E in Africa, F in the USA, and G in the USA and France. The newly discovered genotype H was found in central America \[[@CR2]\]. Some studies indicated that different HBV genotypes revealed different disease profiles. Patients with genotype A had a higher rate of clearance HBV DNA and HBeAg than genotype D, and genotype A was more frequent with liver disease of death than genotype F \[[@CR3]\]. Compared with genotype C, patients with genotype B had less active liver disease as HBV genotype B was more associated with earlier HBeAg seroconversion than genotype C \[[@CR4]\].

Hepatitis B virus infection is a major public health problem worldwide, more than 240 million individuals are infected with chronic HBV, among untreated patients with chronic HBV infection, 15 to 40% may progress to cirrhosis \[[@CR5]\]. As HBV is not eradicable by persons immune response or by antiviral drugs developed so far, the only preventive strategy is vaccination, however vaccine is unsuited with some patients, such as those with chronic kidney disease, human immunodeficiency virus infection, type I diabetes mellitus, and celiac disease \[[@CR6]\] Therefore, development of potent HBV detection methods would provide a better insight into HBV immunopathogenesis and therapy \[[@CR7]\] and guide clinical treatment and affect the prognosis \[[@CR8]\]. To compared with other conventional molecular methods, the recombinase aided amplification (RAA) assay is a new isothermal amplification technology with the advantages of rapidity, simplicity and low-cost and therefore potentially suitable for clinical application. RAA has been successfully used to detect a variety of microbial pathogens \[[@CR9], [@CR10]\] and single nucleotide polymorphisms (SNP) \[[@CR11]\]. In the RAA assay, there are there major proteins: single strand DNA binding protein (SSB), recombinase UvsX (*E. coli*) and DNA polymerase. The recombinase UvsX pairs the specific primers to template DNA, the main function of SSB is to protect the single chain template DNA and DNA polymerase is responsible for amplification and extension, and the amplification process is completed within 20--30 min at 39 °C.

In this study, we developed a RAA assay to detect HBV without DNA extraction. To our best knowledge, it is the first time to report RAA assay for detecting microbial pathogens without nucleic acid extraction.

Methods {#Sec2}
=======

Clinical samples {#Sec3}
----------------

A total of 130 archived suspected HBV infected serum samples, 52 archived and typed HBV (13 genotypes B, 15 C and 13 D) positive serum samples \[[@CR11]\], 10 archived serum samples from healthy donors, stocked human immunodeficiency virus (HIV, *n* = 5) RNA and hepatitis C virus (HCV, *n* = 6) RNA were obtained from Department of Viral Hepatitis of Chinese Center for Disease Control and Prevention. All the serum samples were collected between April 2016 to May 2017 and stored at − 80 °C. All the suspected HBV infected serum samples were HBsAg-positive and from chronic HBV patients (92 male, 38 female) aged from 28 to 46 years. This study was approved (\#IVDC2016014) by the Institutional Review Boards of the National Institute for Viral Disease Control and Prevention, Center for Disease Control and Prevention of China.

DNA extraction and heat treatment (without DNA extraction) {#Sec4}
----------------------------------------------------------

Total DNA was extracted from 200μL of each suspected HBV positive serum sample by using Master Pure Complete DNA and RNA purification kit (Epicenter Technologies, Madison, WI) according to the manufacturer's instructions. The DNA samples were eluted in 50μL of nuclease-free water and stored at− 80 °C until use. In parallel, 1 μL of each serum sample was mixed with 9 μL of extraction buffer from the quick DNA extraction kit (Sangon Biotech, Shanghai, China), the 10μL of mixture was incubated at 80 °C for 3 min then cooled to room temperature until use.

Primers and probes design {#Sec5}
-------------------------

All the available HBV genomes were downloaded from GenBank databases. The sequences were aligned using Vector NTI 11.5.1. We designed HBV RAA primers and probes according to the principle of RAA primer and probe design. We used oligo7 software to carefully analyze dimer formation among themselves (self-dimers) and the formation of secondary structures (hairpins). Besides, we used Primer-BLAST and Blast of NCBI to check and ensure the specificity of primers and probe, respectively. Two optimal primers and one probe sequences are outlined in Table [1](#Tab1){ref-type="table"}.Table 1The information on primer and probe of RAA assayPrimer/probeSequence (5′-3′)Genomic positionProduct size (bp)F-primerATTCGCATGCCCCAACCTCAATCACTCACC311--342443R-primerAATACCACATCATCCATATAACTGAAAGCC721--751ProbeTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCA \[FAM-DT\]\[THF\]\[BHQ-DT\] TCTTGTT GGTTC \[C3-spacer\]391--441Footnote; probe modifications: FAM, 6-carboxyfluorescein; THF, tetrahydrofuran; BHQ, black hole quencher; C3-spacer, 3′ phosphate blocker

Construction of a recombinant plasmid {#Sec6}
-------------------------------------

The targeted sequence (nt311-nt751, GenBank accession no. MH220971.1) was 440 base pair (bp) in length and cloning was done by TsingKe Biotech Corp (Beijing, China). The plasmid DNA was quantified using a NanoDrop (NanoPhotometer N60, Germany). The plasmids were serial 10-fold diluted ranging from 10^5^ to 10^1^ copy/μL and stored − 20 °C to evaluate the sensitivity of RAA assay.

The RAA assay {#Sec7}
-------------

The RAA amplification process was performed in 50 μL reaction volume using a commercial RAA kit (Qitian biological Co., Ltd., Jiangsu, China) which provides all the enzymes and reagents necessary for the amplification according to the manufacturer's instruction. The reaction mixture contained 2 μL of extracted DNA template or 2 μL heat-treated mixture (without DNA extraction), 25 μL of reaction buffer, 15.7 μL of DNase-free water, 2.1 μL of primer F (10 μM), 2.1 μL of primer R (10 μM), 0.6 μL of probe (10 μM), and 2.5 μL of 280 mM magnesium acetate. The tubes were then transferred to the fluorescence detection equipment QT-F7200--0001 (Qitian, Jiangsu, China) set at 39.0 °C for 30 min. A positive control (HBV recombinant plasmid) and negative control (blank control) were included in each run.

Analytical sensitivity, specificity, reproducibility and universality of RAA assay {#Sec8}
----------------------------------------------------------------------------------

The analytical sensitivity analysis of RAA assay was carried out using 10-fold serial dilutions of plasmid ranged from 10^5^ to 10^1^ copies/μL respectively. And the specificity was evaluated by testing of 11 HIV (*n* = 5), HCV RNA (*n* = 6) and 10 serum samples from healthy donors. Besides, twenty replicates were performed in different five days to validate the reproducibility of RAA assay. A total of 41 typed HBV samples containing genotypes B (*n* = 13), C (*n* = 15) and D (n = 13) were used to detect the universality of this method.

Detection of clinical samples by RAA assay {#Sec9}
------------------------------------------

A total of 130 suspected HBV infected serum samples were detected and quantified by a commercial qPCR kit (DAAN GENE, Guangzhou, China) according to the manufacture's instruction. The same amounts of samples were also tested by regular RAA assay. The direct RAA assay was performed at the same time using heat-treated samples without DNA extraction.

Results {#Sec10}
=======

Analytical sensitivity and reproducibility of RAA assay {#Sec11}
-------------------------------------------------------

The analytical sensitivity of the RAA assay for HBV recombinant plasmids was approximately 10^2^ copies/reaction (Fig. [1](#Fig1){ref-type="fig"}). To validate the repeatability of RAA assay, 20 replicates of serially diluted HBV recombinant plasmids (10^5^--10^1^) were assayed and analyzed, 100 and 60% detection rates were achieved at concentrations from 10^5^ to 10^2^ copies/reaction and 10^1^ copies/reaction, respectively (Table [2](#Tab2){ref-type="table"}).Fig. 1Representative HBV RAA reaction curve. A serial dilution ranging from 105 to 100 copies/reaction of recombinant plasmids. NC represents negative controlTable 2The reproducibility of RAA assaySerial diluted HBV DNANo. of replicates testedNo. of detectionDetection rate (%)10^5^202010010^4^202010010^3^202010010^2^202010010^1^201260

Analytical specificity and universality of RAA assay {#Sec12}
----------------------------------------------------

The RAA assay for HBV was negative for HIV, HCV RNA and serum samples from healthy controls (data not shown) but positive for the 41 HBV infected serum samples previously typed by sequencing \[[@CR11]\]. All of the samples (*n* = 13 genotype B, *n* = 15 genotype C, and n = 13 genotype D) can be detected by RAA assay regardless of extraction of nucleic acid or heat-treatment. Thus, the RAA assay demonstrated high specificity for the HBV and broad reaction to different HBV genotypes.

Evaluation of RAA assay using serum samples {#Sec13}
-------------------------------------------

A total of 130 suspected HBV infected serum samples were tested with RAA assay by using extracted DNA and heat-treated samples. qPCR was also performed as a reference method using the same batch of samples. The qPCR tested 117 out of 130 samples positive with virus load range from 1.2 × 10^2^ IU/mL to 8.2 × 10^7^ IU/mL. The results of RAA assay with DNA extraction were in complete agreement with those obtained with qPCR. No false-positives were achieved between the RAA assay without DNA extraction and qPCR. Five samples with viral concentrations ranged from 1.2 × 10^2^ IU/mL to 4.8 × 10^2^ IU/mL mL were positive by qPCR but missed by RAA assay without extraction, displaying a slight decrease of sensitivity of direct RAA compared to qPCR. Compared with q-PCR, the sensitivity of RAA (heat-treatment) was 95.7% the 95% interval of confidence were 0.922--0.992 and the specificity was100%. The detailed comparison of detection results using three methods is present in Table [3](#Tab3){ref-type="table"}.Table 3The detailed comparison of three methods by detecting clinical samplesMethodsq-PCRTotalKappa*P*-valuePositiveNegativeRAA (heat-treatment)Positive1120112Negative513180.8180.025Total1713130RAA (DNA extraction)Positive1170117Negative013131.000\<0.001Total11713130

Discussion {#Sec14}
==========

More than one-third of the world's population has serological evidence of past or present HBV infection \[[@CR12]\]. However, screening for HBsAg, anti-HBs and anti-HBc using enzyme-linked immunosorbent assay (ELISA) is not adequately effective to prevent transfusion-mediated HBV infections. What's more, such method is normally both labor and time intensive. Nucleic acid tests (NATs) have now become a popular method to detect HBV in blood in the chronic phase of HBV infection including the window period as well as OBI \[[@CR13]\]. Nested-PCR \[[@CR14]\], real-time PCR \[[@CR15]\], and loop-mediated isothermal amplification assay (LAMP) \[[@CR16], [@CR17]\] are commonly used NATs for HBV detection. Generally nested-PCR with tedious operation and easy to cross contamination is definitely not suitable for rapid clinical diagnosis. The real-time PCR is ideally used for monitoring the progression of disease and the effectiveness of treatment \[[@CR2]\], but it's difficult to be carried out in laboratories with poor financial condition, limited equipment and lack of skilled personnel.

LAMP assay shows better performance to detect HBV-DNA in resource-limited settings \[[@CR16], [@CR17]\]. For example, N.B.Quoc et al. \[[@CR18]\] developed a closed tube loop-mediated isothermal amplification assay for rapid detection of hepatitis B virus in human blood at 65 °C in less than 60 min and each test costs 5.1\$. In the present study, the RAA assay with DNA extraction revealed the ability to detect HBV infected clinical sample at 39 °C within 30 min. The agreement between qPCR assay and RAA assay with DNA extraction is 100%, and the cost is 3.7\$ of each test. These results showed that the RAA assay was superior to LAMP assays for HBV DNA in terms of the rapidity, simplicity and cost. In addition, the universality of RAA assay in this study was extensively analyzed by using 41 pre-typed HBV samples, suggesting the RAA assay is well adaptable to detect HBV genotypes B, C, the most prevalent types in Asia.

The most attractive feature of proposed RAA assay in this study is to perform the RAA assay without DNA extraction. This avoided the traditional HBV-DNA extraction step and increased the likelihood of in field use of RAA assay. In our initial study, serum samples collected from HBV infected patients were heat-treated under different conditions using different extraction buffers from several commercial kits. We tested different combinations of several temperatures (75 °C, 80 °C and 85 °C,) and duration of time (1 min, 3 min and 5 min), The pretreatment condition was finalized at 80 °C for 3 min.in this study. Previous study reported on the LAMP detection of HBV \[[@CR15]\] using heat-treated (up to 20 min) serum samples without universality analysis. In this study, we just needed less than 30 min to complete RAA detection using heat-treaded clinical samples (80 °C for 3 min) and the RAA sensitivity and specificity was 95.7 and 100% respectively, in comparison with qPCR, indicating that partly processed clinical samples can be used as target template for the RAA assay. Because no sophisticated equipment was required, this assay not only further reduced assay time and cost, but also simplified the detection process. It was even possible to perform the RAA assay combined with lateral flow dipstick (LFD) for visual detection in a closed fist using body heat without the need of any equipment and technical expertise \[[@CR19]\].

Conclusions {#Sec15}
===========

In conclusion, this study demonstrates that the RAA assay is a valuable alternative tool for detection of HBV DNA with the advantages of low cost, high sensitivity, easy implementation, and rapid detection. Given further clinical evaluation with larger sample size from different locations, the RAA assay without DNA extraction will be potentially adaptable for field detection and screening of HBV infection in clinical practice.
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